Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Aridis Pharmaceuticals, Inc. (ARDS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
08/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/20/2023 8-K Quarterly results
06/08/2023 8-K Quarterly results
Docs: "SOURCE Aridis Pharmaceuticals, Inc."
05/25/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Registrant's ...
Docs: "Letter from Baker Tilly US, LLP"
05/09/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
05/01/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "ATTACHMENT 1",
"Note Purchase And Loan Restructuring Agreement This Note Purchase and Loan Restructuring Agreement , dated as of April 26, 2023, is entered into by and among Aridis Pharmaceuticals, Inc., a Delaware corporation , Aridis Biopharmaceuticals, LLC, a Delaware limited liability company , Aridis Pharmaceuticals, C.V., a Netherlands partnership , and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns . A. Company and Investor are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the Securities Act of 1933, as amended , and the rules and regulations promulgated thereunder by the United States Securities and Exchange Commission . B. ARDS Inc. previously issued to Investor the following promissory n...",
"Exhibit 10.2"
04/21/2023 8-K Quarterly results
03/31/2023 8-K Resignation/termination of a director
03/22/2023 8-K Resignation/termination of a director
03/15/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VIA ELECTRONIC MAIL",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March 14, 2023, between Aridis Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purc...",
"Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock"
03/13/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
10/05/2022 8-K Quarterly results
10/05/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/15/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
04/01/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "SOURCE Aridis Pharmaceuticals, Inc."
01/19/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Sales Agreement",
"Opinion of Sheppard Mullin Richter & Hampton, LLP"
01/05/2022 8-K Investor presentation
Docs: "Corporate Presentation of Aridis Pharmaceuticals, Inc"
12/21/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SOURCE Aridis Pharmaceuticals, Inc."
11/30/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Secured Promissory Note",
"Note Purchase Agreement",
"Security Agreement"
11/10/2021 8-K Quarterly results
Docs: "SOURCE Aridis Pharmaceuticals, Inc."
08/12/2021 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "SOURCE Aridis Pharmaceuticals, Inc."
08/12/2021 8-K Quarterly results
08/04/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Common Stock Purchase Warrant",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Opinion of Sheppard, Mullin, Richter & Hampton LLP",
"Form of Securities Purchase Agreement",
"Press Release"
07/26/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "SOURCE Aridis Pharmaceuticals, Inc."
07/19/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "License Agreement between Medimmune Limited and Aridis Pharmaceuticals, Inc.",
"Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca"
07/13/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy